

Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis

Chiara Dianzani^{1,#}, Elena Bellavista^{2,#}, Juliane Liepe³, Claudia Verderio^{4,5}, Morena Martucci², Aurelia Santoro², Annalisa Chiocchetti⁶, Casimiro Luca Gigliotti⁶, Elena Boggio⁶, Benedetta Ferrara¹, Loredana Riganti⁴, Christin Keller^{7,8}, Katharina Janek⁷, Agathe Niewienda⁷, Chiara Fenoglio⁹, Melissa Sorosina¹⁰, Roberto Cantello¹¹, Peter M. Kloetzel^{7,8}, Michael P.H. Stumpf³, Friedemann Paul^{12,13,14}, Klemens Ruprecht^{13,15}, Daniela Galimberti⁹, Filippo Martinelli Boneschi¹⁰, Cristoforo Comi^{6,11}, Umberto Dianzani⁶ & Michele Mishto^{7,8,16,\$}

¹ Department of Drug Science and Technology, University of Turin, 10126 Torino, Italy.

² Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, 40126 Bologna, Italy.

³ Centre for Integrative Systems Biology and Bioinformatics, Department of Life Sciences, Imperial College London, SW7 2AZ London, UK.

⁴ Institute of Neuroscience, Centro Nazionale delle Ricerche (CNR), 20129 Milano, Italy.

⁵ IRCCS Humanitas, 20089 Rozzano, Italy.

⁶ Interdisciplinary Research Centre of Autoimmune Diseases (IRCAD), University of Piemonte Orientale, Amedeo Avogadro, 28100 Novara, Italy.

⁷ Institut für Biochemie, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany.

⁸ Berlin Institute of Health, 10117 Berlin, Germany.

⁹ Neurology Unit, Department of Pathophysiology and Transplantation, University of Milan, "Dino Ferrari" Centre, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, 20100 Milano, Italy.

¹⁰ Department of Neuro-rehabilitation and Laboratory of genetics of Neurological complex disorders, Institute of Experimental Neurology (INSPE) Scientific Institute San Raffaele, 20132 Milano, Italy.

¹¹ Department of Translational Medicine, Section of Neurology, University of Piemonte Orientale, 28100 Novara, Italy

¹² AG Klinische Neuroimmunologie des Neurocure Clinical Research Center, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany.

¹³ Clinical and Experimental Multiple Sclerosis Research Centre - Universitätsmedizin Berlin, 10117 Berlin, Germany.

¹⁴ Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin, Germany

¹⁵ Department of Neurology, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany.

¹⁶ Department of Health Science, University of Piemonte Orientale, 28100 Novara, Italy

[#] Elena Bellavista and Chiara Dianzani equally contributed to the work.


^{\$} To whom the correspondence should be addressed: Michele Mishto, Institut für Biochemie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. Tel: +49(0)30450528-288/071. Email: michele.mishto@charite.de.

List of Supplementary material


Supplementary table 1	Characteristics of healthy control and patient cohorts
Supplementary figure 1	Extracellular 20S proteasome breaks OPN molecules
Supplementary figure 2	Tandem mass spectrometry identification of the six studied fragments of OPN-C generated during <i>in vitro</i> digestion by 20S proteasomes
Supplementary figure 3	Dose-dependent chemotactic effect of proteasome-generated OPN fragments


		Healthy Controls	RRMS Rem	RRMS Rel	CIS
Italian population	Age (y)	36.9 ± 14.8	42.3 ± 10.3	36 ± 10.4	
	Count (n)	62	50	25	
	Gender (M/F)	17/45	22/28	9/16	
	Disease onset (y)	-	41.4 ± 11.2	31.8 ± 9.4	
	Disease duration (y)	-	9.7 ± 7.4	5.0 ± 5.7	
	MSSS	-	3.0 ± 2.2	4.9 ± 2.5	
German population	Age (y)	27.2 ± 4.0	36.8 ± 11.9		32.8 ± 8.8
	Count (n)	50	13		37
	Gender (M/F)	23/27	5/8		15/22
	Disease onset (y)	-	33.1 ± 11.6		31.3 ± 8.8
	Disease duration (y)	-	2.3 ± 1.0		1.2 ± 0.6
	MSSS	-	4.7 ± 2.8		-

Supplementary table 1. Characteristics of healthy control and patient cohorts. Continuous variables are reported as mean ± SD. M = male, F = female, MSSS = Multiple Sclerosis Severity Scale.


a

Supplementary figure 1. Extracellular 20S proteasome breaks OPN molecules. (a) Representative *in vitro* digestion ($n = 3$) of recombinant OPN-FL, OPN-N, OPN-C by different amount of human erythrocyte 20S standard proteasome. The band pattern visible in the samples with 10 µg proteasome resembles that of the proteasome subunits and is thus likely the outcome of a cross-reactivity of the antibodies with such a large amount of proteasome. (b) Degradation kinetics of OPN-FL, OPN-N and OPN-C by T2 20S standard proteasomes are shown by representative Western Blot assay of 4-5 independent experiments. (a-b) The full Western blots are shown. The relevant bands of the OPNs (upper panels) or the proteasome α4 subunits (as controls; lower panels) are marked with an arrow and they are shown in Fig. 1.

b



Supplementary figure 2. Tandem mass spectrometry identification of the six studied fragments of OPN-C generated during *in vitro* digestion by 20S proteasomes. MALDI-tandem mass spectrometry spectra of the peptides WDSRGKDSY-ETSQQL (OPN₂₁₇₋₂₃₀) [peptide score = 59, p = 0.097], KANDESNEHSDVIDSQEL (OPN₂₄₉₋₂₆₆) [peptide score = 101, p = 5.8*10-6], SKVSREFHSHEF (OPN₂₆₇₋₂₇₈) [peptide score = 96, p = 2.1*10-5], KVSREFHSHEF (OPN₂₈₆₋₃₀₆) [peptide score = 72, p = 0.0057], VVDPKSKEEDKHLKFRISHEL (OPN₂₈₆₋₃₀₆) [peptide score = 75, p = 0.0027], and KEEDKHLKFRISHEL (OPN₂₉₂₋₃₀₆) [peptide score = 69, p = 0.0099] identified in the *in vitro* digestion of the substrate OPN-C by erythrocyte 20S proteasome for 20 h. The identity of the peptide OPN₂₁₇₋₂₃₀ is verified by comparison with the fragment pattern of the synthetic analog.



Supplementary figure 3. Dose-dependent chemotactic effect of proteasome-generated OPN fragments. Effect of different concentrations of OPN fragments (10 - 500 nM) on the HUVEC chemotaxis is depicted. Values are reported as percentage of treated vs untreated cells that migrated after 20 h and they are expressed as the mean and the SD of independent experiments ($n = 5 - 14$). Cell migration is measured in the Boyden chamber migration assay.